Journals / The Turkish Journal of Ear Nose and Throat / 2019 / Cilt: 29 - Sayı: 1

Comparative immunohistochemical characteristics of benign and malignant major salivary gland tumors: A retrospective study

Pages
9–20
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
📊
Key Findings & Data:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
💡
Conclusion & Impact:Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p

🔖

Cite This Article

KİREMİTÇi, S., SAK, S. D. (2022). Comparative immunohistochemical characteristics of benign and malignant major salivary gland tumors: A retrospective study. The Turkish Journal of Ear Nose and Throat, Cilt: 29 - Sayı: 1, 9–20. https://ajindex.com/articles/597917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. World Health Organization Classification of Head and Neck Tumours. 4th ed.Lyon: IARC Press; 2017
  2. Sternlicht MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997;48:37-46 3. Sternlicht MD, Safarians S, Rivera SP, Barsky SH. Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Lab Invest 1996;74:781-96
  3. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003;201:562-72
  4. Prasad AR, Savera AT, Gown AM, Zarbo RJ. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med 1999;123:801-6
  5. Ianez RF, Buim ME, Coutinho-Camillo CM, Schultz R, Soares FA, Lourenço SV. Human salivary gland morphogenesis: myoepithelial cell maturation assessed by immunohistochemical markers. Histopathology 2010;57:410-7
  6. Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC. Myoepithelial cell markers in salivary gland neoplasms. Int J Surg Pathol 2005;13:57-65. 8. de Araújo VC, Altemani A, Furuse C, Martins MT, de Araújo NS. Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol 2006;42:1011-6
  7. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7
  8. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24
  9. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-32
  10. Ogawa Y, Toyosawa S, Ishida T, Ijuhin N. Keratin14 immunoreactive cells in pleomorphic adenomasand adenoid cystic carcinomas of salivary glands. Virchows Arch 2000;437:58-68
  11. Iwafuchi H, Mori N, Takahashi T, Yatabe Y.Phenotypic composition of salivary gland tumors: an application of principal [corrected] component analysis to tissue microarray data. Mod Pathol 2004;17:803-10
  12. Nagao T,